ELOXX PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Realized Gain (Loss)
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-30.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2022-03-30
- ELOXX PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2020-12-31 was $0.00.
- ELOXX PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2020-09-30 was $0.00.
- ELOXX PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2020-06-30 was $0.00.
- ELOXX PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2020-03-31 was $0.00.
- ELOXX PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2021 was $0.00.
- ELOXX PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2020 was $0.00.
- ELOXX PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2019 was $0.00.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-30 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $0.00 derived: sum of 2 quarters · filed 2021-03-12 | $0.00 derived: sum of 3 quarters · filed 2021-03-12 | $0.00 10-K · filed 2021-03-12 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | $0.00 derived: sum of 4 quarters · filed 2020-11-06 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $0.00 10-Q · filed 2020-08-07 | $0.00 derived: sum of 3 quarters · filed 2020-08-07 | $0.00 derived: sum of 4 quarters · filed 2020-08-07 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-08 | $0.00 derived: sum of 2 quarters · filed 2020-05-08 | $0.00 derived: sum of 3 quarters · filed 2020-05-08 | $0.00 derived: sum of 4 quarters · filed 2020-05-08 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | $0.00 derived: sum of 2 quarters · filed 2020-03-06 | $0.00 derived: sum of 3 quarters · filed 2020-03-06 | $0.00 10-K · filed 2020-03-06 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $0.00 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-07 | $0.00 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |